The global acute heart failure (AHF) therapeutics market is anticipated to rise at a staggering CAGR during the forecast period. Acute heart failure syndromes comprise a broad range of clinical representations to patient conditions in some aspect of cardiac function. It represents a wider array of pathologies, treatment and a chronic heart condition.
Acute heart failure (AHF) is a common heart condition resulting out of acute and chronic heart conditions leading to cardiac function. However, while the patient opts for treatment, haemodynamic parameters, ventricular function, end-organ perfusion and respiratory function can vary. In such conditions, tailored treatment proves to be the best choice for patients with acute heart failure conditions.
By disorder type, acute heart failure (AHF) therapeutics market is segmented as left-sided heart failure, right-sided heart failure, diastolic failure and systolic failure. Drug category segment comprises angiotensin II receptor blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin-receptor neprilys in inhibitors and beta-blockers. Distribution channel segment for acute heart failure (AHF) therapeutics market comprises retail pharmacies, online pharmacies and hospital pharmacies.
Geographical segmentation for market is North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. North America is likely to gain a significant CAGR during the forecast period due to increase in prevalence of acute heart disease failure cases and increase in prevalence of obesity. Sedentary lifestyle and high risk of heart disease triggers the market demand for heart failure therapeutics.
Asia-Pacific regions are more likely to gain a significant share in international market due to availability of medical infrastructure and rise in number of heart patients are contributing to the regional market growth. European market follows the trend. The key players profiled in the acute heart failure (AHF) therapeutics market report are Bristol-Myers Squibb Company, Amgen Inc, Cytokinetics Inc, Merck & Company, Pfizer Inc, Ono Pharmaceutical Co Ltd, Novartis AG and Cardiorentis AG.
Research Support Specialist, USA